moxidectin and Adrenocortical-Hyperfunction

Canine generalized demodicosis associated with hyperadrenocorticism is often problematic and might be intractable. The aim of this study was to report the efficacy of a weekly application of spot-on moxidectin/imidacloprid in dogs with hyperadrenocorticism and secondary generalized demodicosis.. Dogs with hyperadrenocorticism and secondary generalized demodicosis were included. The condition of hyperadrenocorticism was treated and stabilized with trilostane before and throughout the study period in all dogs.. Average total live adult mite counts before treatment and after four, eight and 12 weeks of spot-on moxidectin/imidacloprid (2.5/10 mg/kg) applications were 20.1±6.3 (range, 13-33), 0.5±0.7 (range, 0-2; 6/11 were negative), 0.2±0.4 (range, 0-1; 9/11 were negative), 0.2±0.4 (range, 0-1; 9/11 were negative) and 0.1±0.3 (range, 0-1; 10/11 were negative) respectively; this difference was significant (P<0.001). Ten of 11 dogs (90.1%) achieved clinical remission, as demonstrated by the absence of demodectic mites at any life stage at monthly scrapings for eight consecutive weeks, and maintained remission throughout the 12-month follow-up period.. The weekly application of spot-on moxidectin/imidacloprid appeared to be effective and safe against generalized adult onset canine demodicosis associated with hyperadrenocorticism.

Topics: Administration, Topical; Adrenocortical Hyperfunction; Animals; Dog Diseases; Dogs; Drug Combinations; Imidazoles; Insecticides; Macrolides; Mite Infestations; Neonicotinoids; Nitro Compounds